Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

hVIVO completes pilot study for hMPV challenge model

(Sharecast News) - Contract research organisation and human challenge trial specialist hVIVO announced the successful completion of a pilot characterisation study for its human metapneumovirus (hMPV) challenge model on Monday. The AIM-traded firm described it as a significant milestone in supporting the development of vaccines and antivirals for hMPV, an area of unmet medical need.

It said the study, conducted at its quarantine facility in Canary Wharf, demonstrated strong infectivity and symptomatic disease in healthy volunteers, confirming the model's viability.

The results would establish proof-of-concept for future human challenge trials using the hMPV strain A2 challenge agent.

hVIVO said it was now marketing the hMPV challenge model, and was planning to complete the full characterisation study in partnership with industry collaborators.

"The pilot hMPV characterisation study in healthy volunteers was designed to test the feasibility of this new model and has been very successful, producing good infectivity rates and clear disease symptoms," said chief scientific officer Dr Andrew Catchpole.

"Like the hVIVO RSV models, I am confident our hMPV model can play a crucial role in speeding up the development of a first vaccine or antiviral for this global pathogen, which is currently causing particular concern in China where a surge in cases has been recorded."

At 1419 GMT, shares in hVIVO were down 34.31% at 17.5p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

Continental to cut 3,000 jobs from auto R&D division
(Sharecast News) - Car parts giant Continental has announced 3,000 job cuts from its global automotive research and development team as part of a move to address efficiency gaps and remain competitive, the German firm said on Tuesday.
Corcel raises £2.72m to support operations
(Sharecast News) - Corcel announced on Tuesday that it has raised £2.72m through an equity placing at a 6.7% premium to the prior day's closing price, with the proceeds set to support operational activities in Angola and Brazil, as well as efforts to expand its interests in the Kwanza Basin, onshore Angola.
Transense reports 36pc jump in half-year revenue
(Sharecast News) - Transense Technologies reported a 36% rise in revenue to £2.46m for the six months ended 31 December on Tuesday, as strong growth enabled strategic investments in operational capabilities.
Riversgold uses option to acquire 80pc of Oracle's Northern Zone Project
(Sharecast News) - Oracle Power confirmed on Tuesday that Riversgold has exercised its option to acquire an 80% interest in the Northern Zone Project in Western Australia, having met the minimum spend requirement set out in the companies' heads of agreement.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.